Babak Kateb, MD, PhD, is the Founding Chairman of the Board, C.E.O., and Scientific Director of the Society for Brain Mapping and Therapeutics (S.B.M.T.), President and Scientific Director of World Brain Mapping Foundation, Pacific Palisades, CA, U.S.A., Director of the National Center for Nano-Bio-Electronics (N.C.N.B.E.), CA, U.S.A., Director of Brain Technology and Innovation Park (B.T.I.P.), Los Angeles, U.S.A., Chairman, Neuroscience20 (Brain, Spine, Mental Health) Initiative, C.E.O. and Co-founder, Aramis TherapeuticsJohn D. Heiss, MD, is the Head of the Clinical Unit of the Surgical Neurology Branch and Program Director of the Neurological Surgery Residency Training Program at the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (N.I.H.) in Bethesda, Maryland. He is actively involved in clinical and translational research to improve the understanding and treatment of Chiari I malformation, syringomyelia, pain, brain tumors, and Parkinson's disease. He is board-certified in neurological surgery and an expert in supervising and conducting clinical trials for C.N.S. disorders. Dr. Heiss received his B.S. in Biomedical Sciences and M.D. from the University of Michigan. In addition, he completed his surgical internship and residency in neurosurgery at the University of Cincinnati College of Medicine. Before joining NINDS, Dr. Heiss was Co-Director of the Neuroscience Intensive Care Unit at the University of Cincinnati.John S. Yu, MD, is a Professor of Neurosurgery, Vice Chair of the Department of Neurosurgery for Neurosurgical Oncology, and the Surgical Director for Neuro-Oncology at Cedars-Sinai, Los Angeles. He also serves as a Member of the Cedars-Sinai Cancer Institute, Los Angeles, U.S.A. Dr. Yu went to Harvard Medical School and then residency at Massachusetts General Hospital.Ming Hsieh, M.S.E.E., PhD, is the Chairman of the Board, President, and C.E.O. Fulgent Genetics. Before that, he served as C.E.O., President, and Chairperson of the board of directors of Cogent, Inc., a biometric identification services and products company. Before his tenure at Cogent, he founded and served as Vice President of A.M.A.X. Technology. Dr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the Nasdaq Global Select Market. Dr. Hsieh received a B.S.E.E. from the University of Southern California in 1983, an M.S.E.E. from the University of Southern California in 1984, and honorary doctoral degrees from the University of Southern California in 2010 and the University of West Virginia in 2011. Dr. Hsieh has been a trustee at the University of Southern California since 2007 and Fudan University in China since 2011. In 2015, Dr. Hsieh was elected to the National Academy of Engineering and the National Academy of Inventors in 2017.Assistant Editors Kevin Morris. M.B.B.S.Academic Affairs Director, Advisory Board Member, and Senior Research Scientist, Society for Brain Mapping and Therapeutics (S.B.M.T.), Pacific Palisades, U.S.A.Joe F. Bolanos, MD Chief Operating Officer, Advisory Board Member, and Senior Research Scientist, Society for Brain Mapping and Therapeutics (S.B.M.T.), Pacific Palisades, U.S.A.

• From Nanotechnology to Nanoneuroscience/Nanoneurosurgery and Nanobioelectronics: A review of Milestones.- Nanoneurology and Nanoneurosurgery.- Nanopolymers and Nanoconjugates for Central Nervous System Theranostics.- Micelles and Liposomes: Lipid Nano-vehicles for Intracerebral Drug Delivery.- Peptide and Protein-Based Nanoparticles.- Endohedral Metallofullerenes, Iron Oxide Agents, and Gold Nanoparticles for Brain Imaging.- Carbon Nanoplatforms and Theranostics for Neurological Disorders.- Dendrimers.- Ligand-Based Targeting of therapeutics and Imaging Agents for Cancer.- Nano-assisted immune-Based Targeting in Cancer.- Directed Drug Convection Using Magnetic Nanoparticles as Therapeutic Carriers: Meeting the Challenge of Specific Brain Pharmacotherapeutics, Non-Ligand-Based Central Nervous System Targeting, Including Magnetic Focusing .- Intralesional and Intraparenchymal Convection-Enhanced Delivery of Nanoparticles.- Therapeutics delivery across the blood-brain barrier.- Nanomedicine Treatment Strategies That Exploit Unique Characteristics of Tumor Vasculature and Microenvironment.- Application of nanoplatforms Focused Ultrasounds Neuromodulation.- Nanosensors.- Implantable Infusion Pumps incorporating nanotechnology.- Application of Nanoplatforms for Intracerebral Neurotransmitter Recording.- State-of-art therapy for Neuronopathic Lysosomal Storage Diseases.- Nanotechnology for Cerebral Aneurysm Treatment.- Improving Treatment of Stroke through Nanotechnology.- Molecular Medical Devices for Nanoneurosurgery.- Nanoneuroscience for Epilepsy Management.- Application of Nanotechnology to Disease of Spine.- Nanoparticle-based Treatment and Imaging of Brain Tumors: Potential and Limitations.- Tumor-Targeted Nanodrugs for Treatment of Primary Brain Tumors.- Application of Nanotechnology in Diagnosis and Treatment of Brain metastasis.- Nanotechnology in Extra-Axial and Pituitary Tumors.- Using Nanoparticles in Diagnosis and Treatment of CNS infection.- Application of Nanotechnology in Movement Disorder.- Nanomedicine in Demyelinating Disease: Application to Diagnosis and Therapey in Multiple Sclerosis.- Application of Nanotechnology in Degenerative Disorders of the Brain.- Brain-Machine Interface and Rehabilitation.- Nanobioelectronics for non-invasive neural therapy.- In Vitro and In Vivo Techniques to Assess Neurotoxicity of Nanoparticles.- Nanorobotics for Neurosurgery.- Imaging and Tracking Therapeutic Cells with Nanoparticles.- Micro and Nanotechnology in Nerve Repair.- Nanotechnology: Applications to Pediatric Neurosurgery.- Food and Drug Administration Regulatory Framework for Nanodrugs and Nanodevices and the Combination.- Key policies issues and initiatives related to Nanoneurosurgery and Nanoneuroscience.- Application of Nanotechnology for Neurovascular Disorders.- Nanoneurosurgery and Radiotherapy.- Inorganic nano-systems for Nanoneuroscience.- Nanobioelectronics: Neuro-ophthalmology and Artificial Retina.- Application of a Conceptual Nanomedical Platform to Facilitate the Mapping of the Human Brain: Survey of Cognitive Functions and Implications.- Clinical trials in nanomedicine.- Nanostructured Boron and Gadolinium Compounds for BNCT (Boron-Neutron Capture Therapy).- The use of microfluidic-based systems in Nanoneuroscience.- Application of 3D (bio)printing in Nanoneuroscience.- Brain Mapping in Glioma patients: from improvement of Clinical outcomes to critical implications in fundamental Neuroscience.- Nanomedicine and Genetherapy.- Nanoneuroscience for COVID19 Brain.- Application of Crisper and nanotechnology for Neurological Disorders.- NASA/National Labs Nanotechnology.- Acute Brain Injuries and Nanotechnology.

Babak Kateb, MD, PhD, is the Founding Chairman of the Board, C.E.O., and Scientific Director of the Society for Brain Mapping and Therapeutics (S.B.M.T.), President and Scientific Director of World Brain Mapping Foundation, Pacific Palisades, CA, U.S.A., Director of the National Center for Nano-Bio-Electronics (N.C.N.B.E.), CA, U.S.A., Director of Brain Technology and Innovation Park (B.T.I.P.), Los Angeles, U.S.A., Chairman, Neuroscience20 (Brain, Spine, Mental Health) Initiative, C.E.O. and Co-founder, Aramis TherapeuticsJohn D. Heiss, MD, is the Head of the Clinical Unit of the Surgical Neurology Branch and Program Director of the Neurological Surgery Residency Training Program at the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (N.I.H.) in Bethesda, Maryland. He is actively involved in clinical and translational research to improve the understanding and treatment of Chiari I malformation, syringomyelia, pain, brain tumors, and Parkinson's disease. He is board-certified in neurological surgery and an expert in supervising and conducting clinical trials for C.N.S. disorders. Dr. Heiss received his B.S. in Biomedical Sciences and M.D. from the University of Michigan. In addition, he completed his surgical internship and residency in neurosurgery at the University of Cincinnati College of Medicine. Before joining NINDS, Dr. Heiss was Co-Director of the Neuroscience Intensive Care Unit at the University of Cincinnati.John S. Yu, MD, is a Professor of Neurosurgery, Vice Chair of the Department of Neurosurgery for Neurosurgical Oncology, and the Surgical Director for Neuro-Oncology at Cedars-Sinai, Los Angeles. He also serves as a Member of the Cedars-Sinai Cancer Institute, Los Angeles, U.S.A. Dr. Yu went to Harvard Medical School and then residency at Massachusetts General Hospital.Ming Hsieh, M.S.E.E., PhD, is the Chairman of the Board, President, and C.E.O. Fulgent Genetics. Before that, he served as C.E.O., President, and Chairperson of the board of directors of Cogent, Inc., a biometric identification services and products company. Before his tenure at Cogent, he founded and served as Vice President of A.M.A.X. Technology. Dr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the Nasdaq Global Select Market. Dr. Hsieh received a B.S.E.E. from the University of Southern California in 1983, an M.S.E.E. from the University of Southern California in 1984, and honorary doctoral degrees from the University of Southern California in 2010 and the University of West Virginia in 2011. Dr. Hsieh has been a trustee at the University of Southern California since 2007 and Fudan University in China since 2011. In 2015, Dr. Hsieh was elected to the National Academy of Engineering and the National Academy of Inventors in 2017.Assistant Editors Kevin Morris. M.B.B.S.Academic Affairs Director, Advisory Board Member, and Senior Research Scientist, Society for Brain Mapping and Therapeutics (S.B.M.T.), Pacific Palisades, U.S.A.Joe F. Bolanos, MD Chief Operating Officer, Advisory Board Member, and Senior Research Scientist, Society for Brain Mapping and Therapeutics (S.B.M.T.), Pacific Palisades, U.S.A.

• From Nanotechnology to Nanoneuroscience/Nanoneurosurgery and Nanobioelectronics: A review of Milestones.- Nanoneurology and Nanoneurosurgery.- Nanopolymers and Nanoconjugates for Central Nervous System Theranostics.- Micelles and Liposomes: Lipid Nano-vehicles for Intracerebral Drug Delivery.- Peptide and Protein-Based Nanoparticles.- Endohedral Metallofullerenes, Iron Oxide Agents, and Gold Nanoparticles for Brain Imaging.- Carbon Nanoplatforms and Theranostics for Neurological Disorders.- Dendrimers.- Ligand-Based Targeting of therapeutics and Imaging Agents for Cancer.- Nano-assisted immune-Based Targeting in Cancer.- Directed Drug Convection Using Magnetic Nanoparticles as Therapeutic Carriers: Meeting the Challenge of Specific Brain Pharmacotherapeutics, Non-Ligand-Based Central Nervous System Targeting, Including Magnetic Focusing .- Intralesional and Intraparenchymal Convection-Enhanced Delivery of Nanoparticles.- Therapeutics delivery across the blood-brain barrier.- Nanomedicine Treatment Strategies That Exploit Unique Characteristics of Tumor Vasculature and Microenvironment.- Application of nanoplatforms Focused Ultrasounds Neuromodulation.- Nanosensors.- Implantable Infusion Pumps incorporating nanotechnology.- Application of Nanoplatforms for Intracerebral Neurotransmitter Recording.- State-of-art therapy for Neuronopathic Lysosomal Storage Diseases.- Nanotechnology for Cerebral Aneurysm Treatment.- Improving Treatment of Stroke through Nanotechnology.- Molecular Medical Devices for Nanoneurosurgery.- Nanoneuroscience for Epilepsy Management.- Application of Nanotechnology to Disease of Spine.- Nanoparticle-based Treatment and Imaging of Brain Tumors: Potential and Limitations.- Tumor-Targeted Nanodrugs for Treatment of Primary Brain Tumors.- Application of Nanotechnology in Diagnosis and Treatment of Brain metastasis.- Nanotechnology in Extra-Axial and Pituitary Tumors.- Using Nanoparticles in Diagnosis and Treatment of CNS infection.- Application of Nanotechnology in Movement Disorder.- Nanomedicine in Demyelinating Disease: Application to Diagnosis and Therapey in Multiple Sclerosis.- Application of Nanotechnology in Degenerative Disorders of the Brain.- Brain-Machine Interface and Rehabilitation.- Nanobioelectronics for non-invasive neural therapy.- In Vitro and In Vivo Techniques to Assess Neurotoxicity of Nanoparticles.- Nanorobotics for Neurosurgery.- Imaging and Tracking Therapeutic Cells with Nanoparticles.- Micro and Nanotechnology in Nerve Repair.- Nanotechnology: Applications to Pediatric Neurosurgery.- Food and Drug Administration Regulatory Framework for Nanodrugs and Nanodevices and the Combination.- Key policies issues and initiatives related to Nanoneurosurgery and Nanoneuroscience.- Application of Nanotechnology for Neurovascular Disorders.- Nanoneurosurgery and Radiotherapy.- Inorganic nano-systems for Nanoneuroscience.- Nanobioelectronics: Neuro-ophthalmology and Artificial Retina.- Application of a Conceptual Nanomedical Platform to Facilitate the Mapping of the Human Brain: Survey of Cognitive Functions and Implications.- Clinical trials in nanomedicine.- Nanostructured Boron and Gadolinium Compounds for BNCT (Boron-Neutron Capture Therapy).- The use of microfluidic-based systems in Nanoneuroscience.- Application of 3D (bio)printing in Nanoneuroscience.- Brain Mapping in Glioma patients: from improvement of Clinical outcomes to critical implications in fundamental Neuroscience.- Nanomedicine and Genetherapy.- Nanoneuroscience for COVID19 Brain.- Application of Crisper and nanotechnology for Neurological Disorders.- NASA/National Labs Nanotechnology.- Acute Brain Injuries and Nanotechnology.

Babak Kateb, MD, PhD, is the Founding Chairman of the Board, C.E.O., and Scientific Director of the Society for Brain Mapping and Therapeutics (S.B.M.T.), President and Scientific Director of World Brain Mapping Foundation, Pacific Palisades, CA, U.S.A., Director of the National Center for Nano-Bio-Electronics (N.C.N.B.E.), CA, U.S.A., Director of Brain Technology and Innovation Park (B.T.I.P.), Los Angeles, U.S.A., Chairman, Neuroscience20 (Brain, Spine, Mental Health) Initiative, C.E.O. and Co-founder, Aramis TherapeuticsJohn D. Heiss, MD, is the Head of the Clinical Unit of the Surgical Neurology Branch and Program Director of the Neurological Surgery Residency Training Program at the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (N.I.H.) in Bethesda, Maryland. He is actively involved in clinical and translational research to improve the understanding and treatment of Chiari I malformation, syringomyelia, pain, brain tumors, and Parkinson's disease. He is board-certified in neurological surgery and an expert in supervising and conducting clinical trials for C.N.S. disorders. Dr. Heiss received his B.S. in Biomedical Sciences and M.D. from the University of Michigan. In addition, he completed his surgical internship and residency in neurosurgery at the University of Cincinnati College of Medicine. Before joining NINDS, Dr. Heiss was Co-Director of the Neuroscience Intensive Care Unit at the University of Cincinnati.John S. Yu, MD, is a Professor of Neurosurgery, Vice Chair of the Department of Neurosurgery for Neurosurgical Oncology, and the Surgical Director for Neuro-Oncology at Cedars-Sinai, Los Angeles. He also serves as a Member of the Cedars-Sinai Cancer Institute, Los Angeles, U.S.A. Dr. Yu went to Harvard Medical School and then residency at Massachusetts General Hospital.Ming Hsieh, M.S.E.E., PhD, is the Chairman of the Board, President, and C.E.O. Fulgent Genetics. Before that, he served as C.E.O., President, and Chairperson of the board of directors of Cogent, Inc., a biometric identification services and products company. Before his tenure at Cogent, he founded and served as Vice President of A.M.A.X. Technology. Dr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the Nasdaq Global Select Market. Dr. Hsieh received a B.S.E.E. from the University of Southern California in 1983, an M.S.E.E. from the University of Southern California in 1984, and honorary doctoral degrees from the University of Southern California in 2010 and the University of West Virginia in 2011. Dr. Hsieh has been a trustee at the University of Southern California since 2007 and Fudan University in China since 2011. In 2015, Dr. Hsieh was elected to the National Academy of Engineering and the National Academy of Inventors in 2017.Assistant Editors Kevin Morris. M.B.B.S.Academic Affairs Director, Advisory Board Member, and Senior Research Scientist, Society for Brain Mapping and Therapeutics (S.B.M.T.), Pacific Palisades, U.S.A.Joe F. Bolanos, MD Chief Operating Officer, Advisory Board Member, and Senior Research Scientist, Society for Brain Mapping and Therapeutics (S.B.M.T.), Pacific Palisades, U.S.A.

• From Nanotechnology to Nanoneuroscience/Nanoneurosurgery and Nanobioelectronics: A review of Milestones.- Nanoneurology and Nanoneurosurgery.- Nanopolymers and Nanoconjugates for Central Nervous System Theranostics.- Micelles and Liposomes: Lipid Nano-vehicles for Intracerebral Drug Delivery.- Peptide and Protein-Based Nanoparticles.- Endohedral Metallofullerenes, Iron Oxide Agents, and Gold Nanoparticles for Brain Imaging.- Carbon Nanoplatforms and Theranostics for Neurological Disorders.- Dendrimers.- Ligand-Based Targeting of therapeutics and Imaging Agents for Cancer.- Nano-assisted immune-Based Targeting in Cancer.- Directed Drug Convection Using Magnetic Nanoparticles as Therapeutic Carriers: Meeting the Challenge of Specific Brain Pharmacotherapeutics, Non-Ligand-Based Central Nervous System Targeting, Including Magnetic Focusing .- Intralesional and Intraparenchymal Convection-Enhanced Delivery of Nanoparticles.- Therapeutics delivery across the blood-brain barrier.- Nanomedicine Treatment Strategies That Exploit Unique Characteristics of Tumor Vasculature and Microenvironment.- Application of nanoplatforms Focused Ultrasounds Neuromodulation.- Nanosensors.- Implantable Infusion Pumps incorporating nanotechnology.- Application of Nanoplatforms for Intracerebral Neurotransmitter Recording.- State-of-art therapy for Neuronopathic Lysosomal Storage Diseases.- Nanotechnology for Cerebral Aneurysm Treatment.- Improving Treatment of Stroke through Nanotechnology.- Molecular Medical Devices for Nanoneurosurgery.- Nanoneuroscience for Epilepsy Management.- Application of Nanotechnology to Disease of Spine.- Nanoparticle-based Treatment and Imaging of Brain Tumors: Potential and Limitations.- Tumor-Targeted Nanodrugs for Treatment of Primary Brain Tumors.- Application of Nanotechnology in Diagnosis and Treatment of Brain metastasis.- Nanotechnology in Extra-Axial and Pituitary Tumors.- Using Nanoparticles in Diagnosis and Treatment of CNS infection.- Application of Nanotechnology in Movement Disorder.- Nanomedicine in Demyelinating Disease: Application to Diagnosis and Therapey in Multiple Sclerosis.- Application of Nanotechnology in Degenerative Disorders of the Brain.- Brain-Machine Interface and Rehabilitation.- Nanobioelectronics for non-invasive neural therapy.- In Vitro and In Vivo Techniques to Assess Neurotoxicity of Nanoparticles.- Nanorobotics for Neurosurgery.- Imaging and Tracking Therapeutic Cells with Nanoparticles.- Micro and Nanotechnology in Nerve Repair.- Nanotechnology: Applications to Pediatric Neurosurgery.- Food and Drug Administration Regulatory Framework for Nanodrugs and Nanodevices and the Combination.- Key policies issues and initiatives related to Nanoneurosurgery and Nanoneuroscience.- Application of Nanotechnology for Neurovascular Disorders.- Nanoneurosurgery and Radiotherapy.- Inorganic nano-systems for Nanoneuroscience.- Nanobioelectronics: Neuro-ophthalmology and Artificial Retina.- Application of a Conceptual Nanomedical Platform to Facilitate the Mapping of the Human Brain: Survey of Cognitive Functions and Implications.- Clinical trials in nanomedicine.- Nanostructured Boron and Gadolinium Compounds for BNCT (Boron-Neutron Capture Therapy).- The use of microfluidic-based systems in Nanoneuroscience.- Application of 3D (bio)printing in Nanoneuroscience.- Brain Mapping in Glioma patients: from improvement of Clinical outcomes to critical implications in fundamental Neuroscience.- Nanomedicine and Genetherapy.- Nanoneuroscience for COVID19 Brain.- Application of Crisper and nanotechnology for Neurological Disorders.- NASA/National Labs Nanotechnology.- Acute Brain Injuries and Nanotechnology.